A Phase 2 interventional study of lyophilised oral capsules with faecal microbiota and Placebo capsules in Rheumatoid Arthritis, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital — 1 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Peking Union Medical College Hospital.
Among the 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital, this one is the only one that started in 2026, is one of 2 in phase 2, and was the 10th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital is open now, in 1 country.
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 50 across the 7 interventional studies, 200 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Rheumatoid by Peking Union Medical College Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this 24-week, single center, randomized, double-blind, placebo-controlled study, the efficacy and safety of lyophilised oral fecal microbiota transplantation in patients with active refractory rheumatoid arthritis will be evaluated.
Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by synovium inflammation and bone and joint erosions, leading to pain, morbidity and increased motality. Nearly half of RA patients displayed incomplete response or intolerance to the anchor drug-methotrexate. Gut microbiota plays an important role in the pathophysiology of RA and abnormal gut microeology has been documented in RA. FMT(fecal microbiota transplantation) is the engraftment of gut microbiota from healthy donors into a recipient, to ideally restore the normal gut microbial community structure. Hopefully, FMT could act as a promising strategy to improve disease control in refractory RA. Oral lyophilised fecal microbiota capsule provides a readily accessible and non-invasive way for FMT. This study will evaluate the efficacy and safety of lyophilised oral FMT in patients with active RA refractory to conventional synthetic disease modifying antirheumatic drugs (csDMARDs)with or without biological DMARDs (bDMARDs)or targeting-synthetic DMARDs (tsDMARDs).
Objectives:
To evaluate the efficacy of lyophilised oral FMT capsule in the treatment of active RA patients refractory to csDMARDs with or without bDMARDs or tsDMARDs; To evaluate the safety of lyophilised oral FMT capsule in the treatment of active RA patients refractory to csDMARDs with or without bDMARDs or tsDMARDs;
DESIGN
This is a Phase 2, randomized, 24-week, double-blind, placebo-controlled study, and 40 patients with active RA refractory to csDMARDs will be randomized in a 1:3 ratio to one of the following 2 parallel treatment arms:
Placebo group: taking placebo capsules with no microbiota inside and continue previous csDMARDs regimen simutaneously; FMT group: taking lyophilised oral capsules with faecal microbiota prepared from health donors and continue previous csDMARDs regimen simutaneously;
Placebo capsules were indistinguishable from FMT capsules by appearance and were stored in identical coded package.
Disease activity and safety profile were evaluated at 8 weeks, 16 weeks and 24 weeks.
Escape:
On week 16, all participants with no response, defined as a \<20% improvement in TJC (tender joint count), SJC (swollen joint count) and CRP (C-reactive protein) from baseline can withdraw and switch to other treatment like biologics.
Endpoints :
Primary endpoint:
ACR 20/50 response rates at 16 weeks.
Secondary endpoint:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
8. Other conditions that investigators consider inappropriate for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants of this group will take lyophilised oral capsules with faecal microbiota prepared from health donors; previous csDMARDs regimen will continue simutaneously.
Drug: lyophilised oral capsules with faecal microbiota
Participants in this group will take placebo capsules with no microbiota inside; previous csDMARDs regimen will continue simutaneously.
Drug: Placebo capsules
Faecal microbiota is extracted from fresh stool collected from strictly screened health donors with canonical procedure, and then lyophilised and prepared into oral capsule.
placebo capsules with the same appearance as FMT capsules but no microbiota inside
ACR 20/50 response rates at 16 weeks
at week 16, the difference in ratio of participants who achieve ACR 20/50 response in two groups.
Time frame: week 16
ACR70 response at 16 weeks
at week 16 and week 24, the difference in ratio of participants who achieve ACR 70 response in two groups.
Time frame: week 16
ACR20/50/70 response at 24 weeks
at week 24, the difference in ratio of participants who achieve ACR 20/50/70 response in two groups.
Time frame: week 24
DAS 28 (CRP) and DAS 28 (ESR) at 16 and 24 weeks
at week 16 and week 24, the difference of diease activity evaluated by DAS 28 (CRP) and DAS 28 (ESR) in two groups
Time frame: week 16 and week 24
EULAR response rates at 16 and 24 weeks;
at week 16 and week 24, the difference of EULAR response evaluated based on DAS 28 (CRP) or DAS 28 (ESR) in two groups
Time frame: week 16 and week 24
Health assessment questionnaire (HAQ) at 16 and 24 weeks;
at week 16 and week 24, Health assessment questionnaire were evaluated and the change from baseline will be compared between two groups
Time frame: week 16 and week 24
Patient assessment of pain (visual analogue scale,VAS)at 16 and 24 weeks;
at week 16 and week 24, pain levels (VAS) of participants were compared between two groups
Time frame: week 16 and week 24
Patient and physician global assessment (PtGA and PhGA) at 16 and 24 weeks;
at week 16 and week 24, global assessment from participants and from care providers will compared between two groups
Time frame: week 16 and week 24
Started Jul 2026 (actual). Primary completion is estimated for Jun 2031, 59 months after the start.
Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 59 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital →